Pharmacological properties of BN82451: A novel multitargeting neuroprotective agent

CNS Drug Reviews

Volumn 13, Issue 3, 2007, Pages 317-332

  Chabrier, Pierre Etienne ^a   Auguet, Michel ^a  

^a Institut Henri Beaufour   (France)

Author keywords

BN82451; Mitochondria; Multitargeting; Neuroprotection

Indexed keywords

4 [2 AMINOMETHYL 1,3 THIAZOL 4YL] 2,6 DI TERT BUTYLPHENOL; BN 82451; CARRAGEENAN; GLUTAMATE RECEPTOR; MALONIC ACID; MINOCYCLINE; NEUROPROTECTIVE AGENT; PROSTAGLANDIN SYNTHASE; SODIUM CHANNEL; UNCLASSIFIED DRUG; VERATRIDINE;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BRAIN INFARCTION; BRAIN ISCHEMIA; CELL DEATH; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ACTIVITY; DRUG MEGADOSE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; ENCEPHALITIS; ENZYME INHIBITION; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PAW EDEMA; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; PHENOLS; THIAZOLES;

EID: 34748846288     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2007.00018.x     Document Type: Review

References (55)

1. Abita JP, Chicheportiche R, Schweitz H, Lazdunski M (1977) Effects of neurotoxins (veratridine, sea anemone toxin, tetrodotoxin) on transmitter accumulation and release by nerve terminals in vitro. Biochemistry 16 : 1838 1844.
2. Andersen JK (2004) Oxidative stress in neurodegeneration: Cause or consequence? Nat Med 10 (Suppl S18 S25.
3. Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF (2001) Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport 12 : 3371 3373.
4. Auvin S, Pignol B, Navet E, Pons D, Marin JG, Bigg D, Chabrier PE (2004) Novel dual inhibitors of calpain and lipid peroxidation. Bioorg Med Chem Lett 14 : 3825 3828.
5. Barclay LR, Vinqvist MR (2000) Do spin traps also act as classical chain-breaking antioxidants? A quantitative kinetic study of phenyl tert-butylnitrone (PBN) in solution and in liposomes. Free Radic Biol Med 28 : 1079 1090.
6. Beal MF (1997) Oxidative damage in neurodegenerative diseases. Neuroscientist 3 : 327 333.
7. Beal MF (1998) Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta 1366 : 211 223.
8. Behl C, Skutella T, Lezoualc'h F, Post A, Widmann M, Newton CJ, Holsboer F (1997) Neuroprotection against oxidative stress by estrogens: Structure-activity relationship. Mol Pharmacol 51 : 535 541.
9. Benavides J, Capdeville C, Dauphin F, Dubois A, Duverger D, Fage D, Gotti B, MacKenzie ET, Scatton B (1990) The quantification of brain lesions with an omega 3 site ligand: A critical analysis of animal models of cerebral ischaemia and neurodegeneration. Brain Res 522 : 275 289.
10. Brouillet E, Jacquard C, Bizat N, Blum D (2005) 3-Nitropropionic acid: A mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 95 : 1521 1540.
11. Cassarino DS, Parks JK, Parker WDJ, Bennett JPJ (1999) The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome C in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta 1453 : 49 62.
12. Chabrier PE, Auguet M, Spinnewyn B, Auvin S, Cornet S, Demerle-Pallardy C, Guilmard-Favre C, Marin JG, Pignol B, Gillard-Roubert V, et al. (1999) BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: A promising neuroprotective strategy. Proc Natl Acad Sci USA 96 : 10824 10829.
13. Chabrier PE, Delaflotte S, Demarquay D, Huchet M, and Auguet M (2002) Involvement of the mitochondria-dependent pathway in tertiobutyl hydroperoxide-induced-cell death: Effect of BN82451. Soc Neurosci Abst: 892.14
14. Cornet S, Spinnewyn B, Delaflotte S, Charnet C, Roubert V, Favre C, Hider H, Chabrier PE, Auguet M (2004) Lack of evidence of direct mitochondrial involvement in the neuroprotective effect of minocycline. Eur J Pharmacol 505 : 111 119.
15. Davis JB, Maher P (1994) Protein kinase C activation inhibits glutamate-induced cytotoxicity in a neuronal cell line. Brain Res 652 : 169 173.
16. De Lombaert S, Ghai RD, Jeng AY, Trapani AJ, Webb RL (1994) Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme. Biochem Biophys Res Commun 204 : 407 412.
17. Delaflotte S, Auguet M, Chabrier, PE (2004) Inhibition of brain and liver mitochondrial swelling by BN82451, a multitargeting neuroprotective agent. Soc Neurosci Abst: 340.17
18. Demerle-Pallardy C, Duverger D, Spinnewyn B, Pirotzky E, Braquet P (1991) Peripheral type benzodiazepine binding sites following transient forebrain ischemia in the rat: Effect of neuroprotective drugs. Brain Res 565 : 312 320.
19. Demerle-Pallardy C, Gillard-Roubert V, Marin JG, Auguet M, Chabrier PE (2000) In vitro antioxidant neuroprotective activity of BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation. J Neurochem 74 : 2079 2086.
20. Desnuelle C, Dib M, Garrel C, Favier A (2001) A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2 : 9 18.
21. Doble A, Kennel P (2000) Animal models of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1 : 301 312.
22. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11 : 81 128.
23. Floyd RA (1999) Neuroinflammatory processes are important in neurodegenerative diseases: An hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Free Radic Biol Med 26 : 1346 1355.
24. Friberg H, Connern C, Halestrap AP, Wieloch T (1999) Differences in the activation of the mitochondrial permeability transition among brain regions in the rat correlate with selective vulnerability. J Neurochem 72 : 2488 2497.
25. Gavino VC, Miller JS, Ikharebha SO, Milo GE, Cornwell DG (1981) Effect of polyunsaturated fatty acids and antioxidants on lipid peroxidation in tissue cultures. J Lipid Res 22 : 763 769.
26. Gonzalez-Scarano F, Baltuch G (1999) Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 22 : 219 240.
27. Greene JG, Porter RH, Eller RV, Greenamyre JT (1993) Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum. J Neurochem 61 : 1151 1154.
28. Hall ED (1993) The role of oxygen radicals in traumatic injury: Clinical implications. J Emerg Med 11 (Suppl 1 31 36.
29. Harnett JJ, Roubert V, Dolo C, Charnet C, Spinnewyn B, Cornet S, Rolland A, Marin JG, Bigg D, Chabrier PE (2004) Phenolic thiazoles as novel orally-active neuroprotective agents. Bioorg Med Chem Lett 14 : 157 160.
30. Hirsch EC, Hunot S, Damier P, Faucheux B (1998) Glial cells and inflammation in Parkinson's disease: A role in neurodegeneration? Ann Neurol 44 : S115 S120.
31. Ikegaya H, Iwase H, Hatanaka K, Sakurada K, Yoshida K, Takatori T (2001) Diagnosis of cyanide intoxication by measurement of cytochrome C oxidase activity. Toxicol Lett 119 : 117 123.
32. Jemmerson R, Dubinsky JM, Brustovetsky N (2005) Cytochrome C release from CNS mitochondria and potential for clinical intervention in apoptosis-mediated CNS diseases. Antioxid Redox Signal 7 : 1158 1172.
33. Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF (2003) Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J Neurochem 86 : 267 272.
34. Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF (2004) Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 88 : 576 582.
35. 2+ and neurodegenerative disease. Eur J Pharmacol 447 : 177 188.
36. Kristal BS, Stavrovskaya IG, Narayanan MV, Krasnikov BF, Brown AM, Beal MF, Friedlander RM (2004) The mitochondrial permeability transition as a target for neuroprotection. J Bioenerg Biomembr 36 : 309 312.
37. Kristian T, Gertsch J, Bates TE, Siesjo BK (2000) Characteristics of the calcium-triggered mitochondrial permeability transition in nonsynaptic brain mitochondria: Effect of cyclosporin A and ubiquinone O. J Neurochem 74 : 1999 2009.
38. Kristian T, Weatherby TM, Bates TE, Fiskum G (2002) Heterogeneity of the calcium-induced permeability transition in isolated non-synaptic brain mitochondria. J Neurochem 83 : 1297 1308.
39. Kriz J, Gowing G, Julien JP (2003) Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann Neurol 53 : 429 436.
40. Marchetti B, Abbracchio MP (2005) To be or not to be (inflamed) - is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends Pharmacol Sci 26 : 517 525.
41. McGeer PL, McGeer EG (1998) Glial cell reactions in neurodegenerative diseases: Pathophysiology and therapeutic interventions. Alzheimer Dis Assoc Disord 12 (Suppl 2 S1 S6.
42. Miralpeix M, Camacho M, Lopez-Belmonte J, Canalias F, Beleta J, Palacios JM, Vila L (1997) Selective induction of cyclo-oxygenase-2 activity in the permanent human endothelial cell line HUV-EC-C: Biochemical and pharmacological characterization. Br J Pharmacol 121 : 171 180.
43. Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT (1989) Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron 2 : 1547 1558.
44. Nagano S, Fujii Y, Yamamoto T, Taniyama M, Fukada K, Yanagihara T, Sakoda S (2003) The efficacy of trientine or ascorbate alone compared to that of the combined treatment with these two agents in familial amyotrophic lateral sclerosis model mice. Exp Neurol 179 : 176 180.
45. Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36 : 2503 2508.
46. 2+-mediated neuronal death in rat brain neuronal cultures by veratridine: Protection by flunarizine. Mol Pharmacol 36 : 525 531.
47. Pearce LL, Bominaar EL, Hill BC, Peterson J (2003) Reversal of cyanide inhibition of cytochrome C oxidase by the auxiliary substrate nitric oxide: An endogenous antidote to cyanide poisoning? J Biol Chem 278 : 52139 52145.
48. Pioro EP, Mitsumoto H (1995) Animal models of ALS. Clin Neurosci 3 : 375 385.
49. Schulz JB, Beal MF (1994) Mitochondrial dysfunction in movement disorders. Curr Opin Neurol 7 : 333 339.
50. Snow RJ, Turnbull J, da Silva S, Jiang F, Tarnopolsky MA (2003) Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience 119 : 661 667.
51. Tan S, Wood M, Maher P (1998) Oxidative stress induces a form of programmed cell death with characteristics of both apoptosis and necrosis in neuronal cells. J Neurochem 71 : 95 105.
52. Tatton WG, Chalmers-Redman RM (1998) Mitochondria in neurodegenerative apoptosis: An opportunity for therapy? Ann Neurol 44 : S134 S141.
53. 2+, mitochondria and selective motoneuron vulnerability: Implications for ALS. Trends Neurosci 28 : 494 500.
54. Winter CA, Risley EA, Nuss GW (1962) Carrageenan-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc Soc Exp Biol 111 : 544 547.
55. Zhang W, Narayanan M, Friedlander RM (2003) Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 53 : 267 270.